Neuromodulation/transmission strategies were frequently evaluated against cognitive deficits (15 evaluations), with a high proportion of evaluations (80%) showing therapeutic effects (Figure 7B), aligning with their aim to ameliorate cognitive deficits without directly targeting tau pathology. This evidence concerns the gene MAPT and Cognitive impairment.